Literature DB >> 8358708

Increased mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta 1 levels during monoterpene-induced regression of mammary tumors.

R L Jirtle1, J D Haag, E A Ariazi, M N Gould.   

Abstract

The monoterpenes represent a potentially new class of breast cancer therapeutic agents. We have shown that d-limonene induces the regression of advanced rat mammary adenocarcinomas. These regressing tumors have an increased cellular concentration of both the mannose-6-phosphate/insulin-like growth factor II receptors and transforming growth factor beta 1. The terpene-induced regression of mammary tumors may result in part from the mitoinhibitory and differentiation properties of active transforming growth factor beta 1. Furthermore, the activation of transforming growth factor beta 1 in these tumors is likely to be facilitated by the increased concentration of the mannose-6-phosphate/insulin-like growth factor II receptors in the mammary tumor cells. Tumors not responding to terpene therapy lacked a rise in the mannose-6-phosphate/insulin-like growth factor II receptor level which may relate to the fact that this gene is hemizygous due to maternal imprinting.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8358708

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  The potential influence of radiation-induced microenvironments in neoplastic progression.

Authors:  M H Barcellos-Hoff
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-04       Impact factor: 2.673

2.  Platelet-derived growth factor is a principal inductive factormodulating mannose 6-phosphate/insulin-like growth factor-II receptorgene expression via a distal E-box in activated hepatic stellate cells.

Authors:  J A Weiner; A Chen; B H Davis
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

Review 3.  The latent transforming growth factor beta binding protein (LTBP) family.

Authors:  R Oklü; R Hesketh
Journal:  Biochem J       Date:  2000-12-15       Impact factor: 3.857

4.  Plasma metabolomic profiles of breast cancer patients after short-term limonene intervention.

Authors:  Jessica A Miller; Kirk Pappan; Patricia A Thompson; Elizabeth J Want; Alexandros P Siskos; Hector C Keun; Jacob Wulff; Chengcheng Hu; Julie E Lang; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-11

5.  Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor.

Authors:  F M Kong; M S Anscher; T Murase; B D Abbott; J D Iglehart; R L Jirtle
Journal:  Ann Surg       Date:  1995-08       Impact factor: 12.969

6.  Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.

Authors:  Glenn Liu; Kurt Oettel; Howard Bailey; Lynn Van Ummersen; Kendra Tutsch; Mary Jane Staab; Dorothea Horvath; Dona Alberti; Rhoda Arzoomanian; Hamied Rezazadeh; James McGovern; Emily Robinson; David DeMets; George Wilding
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

7.  Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene.

Authors:  J D Haag; M N Gould
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Human breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer.

Authors:  Jessica A Miller; Julie E Lang; Michele Ley; Ray Nagle; Chiu-Hsieh Hsu; Patricia A Thompson; Catherine Cordova; Amy Waer; H-H Sherry Chow
Journal:  Cancer Prev Res (Phila)       Date:  2013-04-03

9.  Human metabolism of the experimental cancer therapeutic agent d-limonene.

Authors:  P L Crowell; C E Elson; H H Bailey; A Elegbede; J D Haag; M N Gould
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 10.  Insulin-like growth factor mediated stromal-epithelial interactions in human breast cancer.

Authors:  M J Ellis; C Singer; A Hornby; A Rasmussen; K J Cullen
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.